NCT04969549

Brief Summary

The study consists of an open label trial designed to treat adult depression with TBS. Our aim is to build capacity in neuroimaging analyses by performing magnetic resonance imaging (MRI) assessments at baseline and after 7-10 days of treatment onset in 70 patients. The scientific goal is to test a hypothesis about treatment action: that TBS will reduce negative bias (which causally maintains negative mood) after 1 week of treatment, and patients who show this neurocognitive change will be the ones who go on to respond clinically after 6 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for not_applicable depression

Timeline
Completed

Started May 2021

Typical duration for not_applicable depression

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 13, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 16, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 20, 2021

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 28, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 28, 2023

Completed
Last Updated

February 26, 2024

Status Verified

February 1, 2024

Enrollment Period

1.5 years

First QC Date

July 16, 2021

Last Update Submit

February 22, 2024

Conditions

Keywords

depressionTBSfMRIresponse predictors

Outcome Measures

Primary Outcomes (1)

  • Change in Hamilton Depression Rating Scale scores (17-item version)

    Clinician-administered depression assessment scale. Score range = 0 - 52 (higher scores mean worse outcome).

    Week 0 (baseline) and Week 6

Secondary Outcomes (6)

  • Change in Montgomery-Asberg Depression Rating Scale scores (MADRS)

    Week 0 (baseline) and Week 6

  • Change in Young Mania Rating Scale (YMRS) scores

    Week 0 (baseline) and Week 6

  • Facial Expression Recognition Test (FERT)

    Week 0 (baseline) and Week 2.

  • Change in Positive and Negative Affect Schedule scores (PANAS)

    Week 0 (baseline) and Week 6

  • Change in State-Trait Anxiety Inventory scores (STAI-T and STAI-S)

    Week 0 (baseline) and Week 6

  • +1 more secondary outcomes

Study Arms (1)

Theta-burst stimulation (TBS)

OTHER

Receive active iTBS, 1800 pulses, 100% MT over dlPFC.

Other: Theta burst stimulation

Interventions

It consists of 20 sessions of iTBS over the dlPFC.

Also known as: TBS
Theta-burst stimulation (TBS)

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto de Psiquiatria

São Paulo, São Paulo, 05403-903, Brazil

Location

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Andre R Brunoni, MD, PhD

    FACULDADE DE MEDICINA DA USP

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Active TBS.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of the Medical School of the University of Sao Paulo (FMUSP), Principal Investigator

Study Record Dates

First Submitted

July 16, 2021

First Posted

July 20, 2021

Study Start

May 13, 2021

Primary Completion

November 28, 2022

Study Completion

November 28, 2023

Last Updated

February 26, 2024

Record last verified: 2024-02

Locations